INVO Fertility, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVF research report →
Range $20 – $20
Price Chart
About the company
INVO Fertility, Inc. is a profitable enterprise primarily focused on delivering fertility services. Beyond this core business, the company actively develops clinical-stage therapies targeting oncology and autoimmune disorders.
- CEO
- Steven Shum
- IPO
- 2020
- Employees
- 41
- HQ
- Sarasota, FL, US
Get TickerSpark's AI analysis on IVF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.10M
- P/E
- -0.15
- Fwd P/E
- 1.26
- PEG
- -0.00
- P/S
- 0.26
- P/B
- 0.09
- EV/EBITDA
- -0.28
- Div Yield
- 0.00%
- Gross Margin
- 33.18%
- Op Margin
- -72.16%
- Net Margin
- -59.91%
- ROE
- -33.77%
- ROIC
- -25.84%
Latest fiscal year · YoY change
- Revenue
- $6.84M+4.7%
- Gross Profit
- $2.53M-12.0%
- Op Income
- $-7,237,356
- Net Income
- $-23,323,054-156.4%
- EPS
- $-214.64-611.0%
- OCF Growth
- -135.8%
- FCF Growth
- -123.5%
- 52W High
- $91.60
- 52W Low
- $1.59
- 50D MA
- $2.79
- 200D MA
- $7.22
- Beta
- 2.42
- RSI (14)
- 33
- Avg Volume
- 51.75K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
INVO Bioscience said Q2 showed stronger clinic and product growth, a major profitable acquisition, and a clearer path toward breakeven in 2024.· August 14, 2023
- Q2 revenue was approximately $316,000, up from approximately $146,000 a year ago, while all three clinics generated $712,000 versus $291,000 last year.
- Adjusted EBITDA loss improved to approximately $1.6 million from approximately $2.2 million, helped by lower operating expenses and the end of 510(k) program costs.
- The company closed the Wisconsin Fertility Institute acquisition, which management said had more than $5 million of revenue and about $1.7 million of net income last year.
- INVO said product revenue increased 82% in the quarter and that the new 5-day FDA clearance should support marketing, patient awareness, and clinic adoption.
- Management said Tampa is expected to open in the next 60 to 90 days and still targets operating cash flow breakeven in 2024.
Revenue for the quarter was approximately $316,000, compared with approximately $146,000 in the prior-year period. Consolidated service revenue from the Atlanta INVO Center was approximately $254,000, or 81% of revenue, and product revenue was the remaining 19%; product revenue increased 82% year over year. Revenue from all three clinics totaled $712,000 versus $291,000 in the prior-year period. Operating expenses decreased to approximately $2.4 million from approximately $2.8 million, and adjusted EBITDA loss improved to approximately $1.6 million from approximately $2.2 million. At June 30, 2023, the company had approximately $112,000 in cash and $1.3 million in debt. Since quarter end, it repaid approximately $140,000 of convertible debt and raised approximately $4.5 million in gross proceeds in a public offering of common stock and warrants. Management expects 2023 clinic revenue to continue building, mainly from Wisconsin and to a lesser degree Tampa, and reiterated a target for operating cash flow breakeven in 2024.
Steve Shum framed the quarter as a turning point, emphasizing the closing of Wisconsin Fertility Institute as a transformative step that shifts INVO from a device company toward an integrated fertility services provider. He said the model is designed to capture more revenue per treatment, citing roughly $4,500 to $7,000 per IVC cycle versus about $400 per device sale, and he highlighted the company’s goal of scaling profitable clinic operations. His tone was optimistic and confident, pointing to Tampa, Wisconsin integration, and the 5-day labeling expansion as key drivers of future growth.
Andrea Goren detailed that Q2 revenue was approximately $316,000 versus approximately $146,000 last year, with adjusted EBITDA loss narrowing to approximately $1.6 million from approximately $2.2 million. She said operating expenses fell to approximately $2.4 million from approximately $2.8 million, largely due to lower personnel, marketing, stock-based compensation, and R&D costs. She also noted approximately $112,000 in cash and $1.3 million in debt at June 30, plus the post-quarter repayment of approximately $140,000 of convertible debt and a public offering that raised approximately $4.5 million gross. Management said the recent expense reductions, together with Wisconsin, should further improve EBITDA.
Analysts focused on the importance of the 510(k) clearance for 5-day incubation and how it changes both competitive messaging and clinic growth. Management said the longer incubation period helps correct what they view as a market misconception that INVOcell has inferior outcomes, and it lets clinics market the technology more proactively with validated data. The analyst also asked about the assumptions behind 2024 breakeven; management said it is based on incremental growth at Wisconsin, the Tampa opening, current clinic trajectory, and about 30% reductions in corporate costs, without assuming additional acquisitions.
Management pointed to multiple catalysts now working together: a profitable acquired clinic, improving performance at existing centers, the end of 510(k) costs, and a new 5-day label that could strengthen marketing and patient conversion. They also said Wisconsin and future centers could help move the company toward operating cash flow breakeven in 2024.
The company still reported a net loss and adjusted EBITDA loss, and cash was only approximately $112,000 at quarter-end before the post-quarter financing. Management’s breakeven plan depends on successful integration of Wisconsin, the Tampa launch, and maintaining growth in current clinics, while they also acknowledged competitive messaging has been a disadvantage because rivals have cited the older 3-day data.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 1.19M
- Float Shares
- 1.19M
of shares held by institutions
9 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Stonex Group Inc. | 38.52K | ▲ 22.81K |
| Jane Street Group, LLC | 31.92K | ▲ 31.92K |
| Virtu Financial LLC | 21.15K | ▼ 42.02K |
| Commonwealth Equity Services, LLC | 13.00K | ▲ 13.00K |
| Tower Research Capital LLC (Trc) | 3.34K | ▼ 4.82K |
| Ubs Group AG | 2.81K | ▲ 2.81K |
| Robinhood Markets, Inc. | 39 | ▲ 39 |
| Jpmorgan Chase & Co | 2 | ▲ 2 |
| Citigroup Inc | 1 | ▲ 1 |
| Danske Bank A/S | 1 | 0 |
| Caitong International Asset Management Co., Ltd | 1 | ▼ 37 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 30, 25 | Krigsvold Terah Renee | other | 0 |
| Dec 30, 25 | Krigsvold Terah Renee | other | 0 |
| Dec 30, 25 | Krigsvold Terah Renee | other | 0 |
| Dec 30, 25 | Krigsvold Terah Renee | other | 0 |
| Dec 29, 22 | Krigsvold Terah Renee | other | 0 |
| Jan 13, 23 | Krigsvold Terah Renee | other | 0 |
| Jan 31, 23 | Krigsvold Terah Renee | other | 0 |
| Dec 30, 25 | Krigsvold Terah Renee | other | 0 |
| Dec 3, 25 | Szot Matthew K | sell | 4 |
| Dec 4, 25 | Szot Matthew K | other | 3 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IVF coverage
Recent articles, reports, and earnings notes.
No research on IVF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IVF report →Head to Head Contrast: INVO Fertility (NASDAQ:IVF) vs. McKesson (NYSE:MCK)
defenseworld.net · Nov 17
INVO Fertility Reports Third Quarter 2026 Results Highlighting 28% Clinic Revenue Growth and Continued Positive Clinic-Level Adjusted EBITDA
globenewswire.com · Nov 16
INVO Fertility Partners with PatientFi to Help Make Fertility Treatment More Affordable
globenewswire.com · Nov 5
INVO Fertility Announces a 1:4 Reverse Stock Split Effective Pre-Market Opening on October 30, 2026
globenewswire.com · Oct 27
Head to Head Comparison: Agilon Health (NYSE:AGL) & INVO Fertility (NASDAQ:IVF)
defenseworld.net · Oct 11
INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference
globenewswire.com · Sep 25
Financial Analysis: INVO Fertility (NASDAQ:IVF) vs. P3 Health Partners (NASDAQ:PIIIW)
defenseworld.net · Sep 2
INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
globenewswire.com · Aug 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.